Clinical Trial Update: CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CBM588 capsules in combination with nivolumab and ipilimumab for advanced or metastatic renal cell carcinoma, including clear cell and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• CBM588
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Osel, Inc. | Conditions: Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Status: RECRUITING